Evidence map›Paper›PMID 40208112›Full record

ArticleEndocrinology2025

Ovarian-Specific Cyp17A1 Overexpression in Female Mice: A Novel Model of Endogenous Testosterone Excess.

Serene Joseph, Vaibhave Ubba, Zhiqiang Wang, Mingxiao Feng, Milan K dSilva, Sofia Suero, Danielle Waheed, Nathaniel W Snyder, Xiaofeng Yang, Hong Wang and 3 more

Abstract read
In one paragraph

Article in Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Serene JosephCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Vaibhave UbbaCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Zhiqiang WangDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Mingxiao FengDepartment of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Milan K dSilvaCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Sofia SueroCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Danielle WaheedCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Nathaniel W SnyderCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Xiaofeng YangCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Hong WangCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
JoAnne S RichardsDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
CheMyong J KoDepartment of Comparative Biosciences, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802, USA.
Sheng WuCenter for Metabolic Disease Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.ORCID 0000-0003-2944-0475

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
IL-35 inhibits gut microbiota-produced uremic toxin-accelerated endothelial cell activationR01HL147565 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI YANG, XIAOFENG · 2019 to 2022
$2.6M
LysoPI/GPR55 pathway promotes endothelial activation, vascular inflammation and atherosclerosisR01HL163570 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI Xiaofeng Yang · 2023 to 2026
$2.6M
NHLBI NIH HHS R01 HL147565NHLBI NIH HHS R01 HL163570NIH HHS P51 OD011106NIH HHS R00-HD068130 04
6 · The paper itself

Abstract

Excessive androgen levels can severely affect female health. However, most existing models of androgen excess rely on exogenous androgen administration, which does not fully capture the effect of elevated local ovarian testosterone on reproductive and metabolic functions. Here, we report the development of a novel hyperandrogenic mouse model, Cyp17TM-625, generated by combining CRISPR-Cas9 and a Tet-On doxycycline system to induce Cyp17A1 overexpression in ovarian theca-interstitial cells. As a result, Cyp17TM-625 mice exhibited significantly elevated Cyp17A1 messenger RNA and protein levels, accompanied by increased testosterone concentrations without alterations in basal levels of estradiol, progesterone, luteinizing hormone, or follicle-stimulating hormone. These mice demonstrated subfertility, evident by smaller and fewer litters, prolonged estrous cycles, and an increased number of unhealthy follicles with abnormally shaped oocytes. Despite these marked reproductive changes, body weight and glucose homeostasis remained comparable to Con-625 mice. Notably, withdrawal of doxycycline reversed testosterone overexpression and restored fertility over time. This model recapitulates reproductive dysfunction but not the metabolic disturbances, commonly observed in exogenous androgen models. The Cyp17TM-625 mouse line is a unique model for investigating the effects of local excess androgens on ovarian function. It also serves as a valuable tool for studying fertility restoration following the withdrawal of testosterone.

Indexed as

HyperandrogenismOvarySteroid 17-alpha-HydroxylaseTestosteroneAnimalsDisease Models, AnimalEstrous CycleFemaleMiceMice, TransgenicSteroid 17-alpha-HydroxylaseTestosteronehyperandrogenismovaryreproductiontestosterone

Identifiers

PMID40208112
PMCPMC12006740

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.